SAB Biotherapeutics, Inc. (NASDAQ:SABS – Free Report) – Equities researchers at Brookline Capital Markets issued their Q3 2026 earnings estimates for SAB Biotherapeutics in a report released on Friday, May 15th. Brookline Capital Markets analyst K. Raja expects that the company will post earnings per share of ($0.25) for the quarter. The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($1.22) per share. Brookline Capital Markets also issued estimates for SAB Biotherapeutics’ Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($1.08) EPS, FY2027 earnings at ($1.07) EPS, FY2028 earnings at ($1.17) EPS, FY2029 earnings at ($0.79) EPS and FY2030 earnings at $1.17 EPS.
A number of other research analysts have also recently weighed in on SABS. Wall Street Zen cut shares of SAB Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. HC Wainwright lifted their price objective on shares of SAB Biotherapeutics from $7.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Chardan Capital lifted their price objective on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, March 11th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of SAB Biotherapeutics in a report on Friday, April 10th. Finally, Zacks Research raised shares of SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, SAB Biotherapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.
SAB Biotherapeutics Trading Down 0.3%
NASDAQ SABS opened at $3.55 on Wednesday. The company has a market capitalization of $180.87 million, a PE ratio of -1.68 and a beta of 0.55. The company has a fifty day moving average of $3.85 and a 200 day moving average of $3.84. SAB Biotherapeutics has a 1 year low of $1.60 and a 1 year high of $6.60. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.45 and a quick ratio of 11.45.
SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.15).
Hedge Funds Weigh In On SAB Biotherapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the company. PNC Financial Services Group Inc. acquired a new position in shares of SAB Biotherapeutics in the 1st quarter worth approximately $29,000. State of Wyoming acquired a new position in shares of SAB Biotherapeutics in the 4th quarter worth approximately $34,000. ADAR1 Capital Management LLC lifted its holdings in shares of SAB Biotherapeutics by 75.6% in the 4th quarter. ADAR1 Capital Management LLC now owns 26,344 shares of the company’s stock worth $99,000 after acquiring an additional 11,344 shares during the last quarter. State Street Corp acquired a new position in shares of SAB Biotherapeutics in the 4th quarter worth approximately $49,000. Finally, Fifth Lane Capital LP acquired a new position in shares of SAB Biotherapeutics in the 4th quarter worth approximately $56,000. 7.82% of the stock is currently owned by institutional investors and hedge funds.
About SAB Biotherapeutics
SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.
The company’s lead programs are directed primarily at infectious diseases.
Read More
- Five stocks we like better than SAB Biotherapeutics
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
